API | blinatumomab

blinatumomab (blincyto) Report issue

Biologics mAb Multi-specific Orphan Drug ^FDA Approved ^FDA Accelerated Approval ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Blinatumomab, sold under the brand name Blincyto, and known informally as blina, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval. Blinatumomab is given via intravenous infusion. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
blinatumomab

More Chemistry

Pharmacology

Mechanisms of Action:
- B-lymphocyte antigen CD19 (Homo sapiens) ^UniProt
Multi-specific: Yes
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Organizations (71)

Research & Development (71)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (32)

Approved Indications (1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Experimental Indications - Clinical Trial Phases 1-4 (32)

Antigens, CD19 (Phase 1/Phase 2)

Burkitt Lymphoma (Phase 1)

Down Syndrome (Phase 3)

Fusion Proteins, bcr-abl (Phase 2)

Hodgkin Disease (Phase 2/Phase 3)

Leukemia (Phase 3)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Multiple Myeloma (Early Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasm, Residual (Phase 2)

Neoplasms (Phase 2)

Pediatrics (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Sarcoma, Myeloid (Phase 2)

Translocation, Genetic (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 90
# of Trial Organizations: 71

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue